At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Aug 7, 2026 at 16:01 ET
Two senior R&D executives at Incyte (President and Chief Scientific Officer) sold a combined $2.18M of stock in the week following the Q2 earnings beat. The sales are trivial relative to Incyte's $24B market cap (0.009%) and likely reflect routine post-earnings window rebalancing and derivative exercise coverage, not a bearish signal.
- Pablo J. Cagnoni (President, Global Head of R&D) sold $1.90M on 2026-07-31; Patrick A. Mayes (EVP & Chief Scientific Officer) sold ~$274K on 2026-08-05 after exercising options
- Total cluster value: $2.18M (0.009% of $24B market cap)
- Cluster occurred 3–10 days after Incyte's Q2 2026 earnings (8-K filed 7/28), which beat consensus but included a one-time CMS settlement benefit
- Mayes' sales corresponded with derivative exercises at $105–$106 strike, suggesting tax- or exercise-cost coverage
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access